Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

ALAWAY

KETOTIFEN FUMARATE

Standard Dose
EQ 0.025% BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ALAWAY is listed in Drugs@FDA under application 208158 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient KETOTIFEN FUMARATE Form and strength SOLUTION/DROPS;OPHTHALMIC - EQ 0.025% BASE Sponsor BAUSCH AND LOMB INC Submission history Latest submission status date: 2020-09-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALAWAY is listed in Drugs@FDA under application 208158 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient KETOTIFEN FUMARATE Form and strength SOLUTION/DROPS;OPHTHALMIC - EQ 0.025% BASE Sponsor BAUSCH AND LOMB INC Submission history Latest submission status date: 2020-09-24 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.